Paediatric Fungal infections

This section summarises published information regarding the concepts in managing invasive fungal infections in children, with specific reference to Aspergillus.

Broadly there are two sections comprising diagnosis and treatment regimes. The data here are sourced and summarised from a series of publications in Clinical Microbiology Infect. 16(9), 1319-53, 2010 by Groll et alWalsh et alDornbusch et al& all these references are more comprehensive than the data compiled here and we recommend referral to the original publications for further detail. 
To view any links to publication please register your name with the site here.

Children and in particular neonates and young infants, are a unique patient population, particularly with respect to fungal infections. 
Invasive fungal infections are dificult to diagnose - but response to treatment and outcome is dependent on a prompt initial diagnosis and the initiation of treatment.

Epidemiology and Clinical Trials

The epidemiology, presentation and pre-disposing conditions show significant differences in paediatric versus adult patients. 
The use of antifungal agents in this patient group requires an understanding of pharmacodynamics and safety issues - which accumulating evidence suggests can not always be empirically derived from data collected on usage in adult groups.

Many antifungal clinical trials have previously excluded paediatric groups so there is a lack of trials of large cohorts- but there is data in the literature for smaller cohorts of paediatric patients- for various antifungal treatments.
New antifungals are continually going into trials - however the need for evaluation in paediatric patients is great.

This website specialises in Aspergillus infections - but the lack of paediatric data has meant that we have included data for other types of fungal infections - where it may be useful. 

Computed content type (Paediatrics): 


Paediatric articles

Displaying 1 - 10 of 169
Author year
Treatment of Aspergillus fumigatus infection with posaconazole delayed-release tablets. Shearin S, Bell T. 2018
Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Allegra S, Fatiguso G, Francia S, Pirro E, Carcieri C, Cusato J, Nicolò A, Avataneo V, Perri GD, D'Avolio A. 2018
Chronic Rhinosinusitis in Children: Pathophysiology, Evaluation, and Medical Management. Heath J, Hartzell L, Putt C, Kennedy JL 2018
Neonatal Mucormycosis with Gastrointestinal and Cutaneous involvement. Devi RU, Balachandran A, Kamalarathnam CN, Pappathi S. 2018
Self-resolving superficial primary cutaneous mucormycosis in a 7-week-old infant. Jones MU, Flores MS, Vereen RJ, Szabo SR, Logemann NF, Eberly MD. 2018
Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. Santolaya ME, Alvarez AM, Acuña M, Avilés CL, Salgado C, Tordecilla J, Varas M, Venegas M, Villarroel M, Zubieta M, Farfán M, de la Maza V, Vergara A, Valenzuela R, Torres JP. 2018
Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital Valenzuela R, García P, Barraza M, Palma J, Catalán P, Santolaya ME, Torres JP, Morales J. 2018
Primary cutaneous aspergillosis at the site of cyanoacrylate skin adhesive in a neonate. Kusari A, Sprague J, Eichenfield LF, Matiz C, Barrio VR 2018
Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease. Slack MA, Thomsen IP. 2018
Uso de posaconazol en niños: experiencia en un hospital pediátrico de alta complejidad [Use of posaconazole in children: Experience in a tertiary pediatric hospital]. [Article in Spanish] Rosanova MT, Voto C, Mussini MS, Sarkis C, Gómez S, Sberna N, Carnovale S, Caracciolo B, Lede R. 2018